Calf Clinical Model of Cryptosporidiosis for Efficacy Evaluation of Therapeutics

Michael W Riggs, Deborah A. Schaefer

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Cryptosporidiosis, caused by the apicomplexan parasite Cryptosporidium parvum, is a moderate-to-severe diarrheal disease now recognized as one of the leading causes of morbidity and mortality in livestock globally, and in humans living in resource-limited parts of the world, particularly those with AIDS or malnourished individuals. This recognition has fueled efforts for the discovery of effective therapeutics. While recent progress in drug discovery has been encouraging, there are presently no acceptably effective parasite-specific drugs for the disease. The urgent need for new drug discovery or drug repurposing has also increased the need for refined animal models of clinical disease for therapeutic efficacy evaluation. Here, we describe an acute model of cryptosporidiosis using newborn calves to evaluate well-defined clinical and parasitological parameter outcomes, including the effect on diarrhea severity and duration, oocyst numbers produced, and multiple measures of clinical health. The model is highly reproducible and provides unequivocal direct measures of treatment efficacy on diarrhea severity and parasite replication.

Original languageEnglish (US)
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages253-282
Number of pages30
DOIs
StatePublished - Jan 1 2020

Publication series

NameMethods in Molecular Biology
Volume2052
ISSN (Print)1064-3745
ISSN (Electronic)1940-6029

Fingerprint

Cryptosporidiosis
Parasites
Drug Discovery
Diarrhea
Drug Repositioning
Cryptosporidium parvum
Animal Disease Models
Oocysts
Livestock
Acquired Immunodeficiency Syndrome
Therapeutics
Morbidity
Mortality
Health
Pharmaceutical Preparations

Keywords

  • Bovine model
  • Clinical evaluation
  • Cryptosporidiosis
  • Cryptosporidium
  • Diarrhea quantitation
  • Oocyst quantitation
  • Therapeutic evaluation

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Riggs, M. W., & Schaefer, D. A. (2020). Calf Clinical Model of Cryptosporidiosis for Efficacy Evaluation of Therapeutics. In Methods in Molecular Biology (pp. 253-282). (Methods in Molecular Biology; Vol. 2052). Humana Press Inc.. https://doi.org/10.1007/978-1-4939-9748-0_15

Calf Clinical Model of Cryptosporidiosis for Efficacy Evaluation of Therapeutics. / Riggs, Michael W; Schaefer, Deborah A.

Methods in Molecular Biology. Humana Press Inc., 2020. p. 253-282 (Methods in Molecular Biology; Vol. 2052).

Research output: Chapter in Book/Report/Conference proceedingChapter

Riggs, MW & Schaefer, DA 2020, Calf Clinical Model of Cryptosporidiosis for Efficacy Evaluation of Therapeutics. in Methods in Molecular Biology. Methods in Molecular Biology, vol. 2052, Humana Press Inc., pp. 253-282. https://doi.org/10.1007/978-1-4939-9748-0_15
Riggs MW, Schaefer DA. Calf Clinical Model of Cryptosporidiosis for Efficacy Evaluation of Therapeutics. In Methods in Molecular Biology. Humana Press Inc. 2020. p. 253-282. (Methods in Molecular Biology). https://doi.org/10.1007/978-1-4939-9748-0_15
Riggs, Michael W ; Schaefer, Deborah A. / Calf Clinical Model of Cryptosporidiosis for Efficacy Evaluation of Therapeutics. Methods in Molecular Biology. Humana Press Inc., 2020. pp. 253-282 (Methods in Molecular Biology).
@inbook{5dc4580f996f43f28a2bfca0b885e9ea,
title = "Calf Clinical Model of Cryptosporidiosis for Efficacy Evaluation of Therapeutics",
abstract = "Cryptosporidiosis, caused by the apicomplexan parasite Cryptosporidium parvum, is a moderate-to-severe diarrheal disease now recognized as one of the leading causes of morbidity and mortality in livestock globally, and in humans living in resource-limited parts of the world, particularly those with AIDS or malnourished individuals. This recognition has fueled efforts for the discovery of effective therapeutics. While recent progress in drug discovery has been encouraging, there are presently no acceptably effective parasite-specific drugs for the disease. The urgent need for new drug discovery or drug repurposing has also increased the need for refined animal models of clinical disease for therapeutic efficacy evaluation. Here, we describe an acute model of cryptosporidiosis using newborn calves to evaluate well-defined clinical and parasitological parameter outcomes, including the effect on diarrhea severity and duration, oocyst numbers produced, and multiple measures of clinical health. The model is highly reproducible and provides unequivocal direct measures of treatment efficacy on diarrhea severity and parasite replication.",
keywords = "Bovine model, Clinical evaluation, Cryptosporidiosis, Cryptosporidium, Diarrhea quantitation, Oocyst quantitation, Therapeutic evaluation",
author = "Riggs, {Michael W} and Schaefer, {Deborah A.}",
year = "2020",
month = "1",
day = "1",
doi = "10.1007/978-1-4939-9748-0_15",
language = "English (US)",
series = "Methods in Molecular Biology",
publisher = "Humana Press Inc.",
pages = "253--282",
booktitle = "Methods in Molecular Biology",

}

TY - CHAP

T1 - Calf Clinical Model of Cryptosporidiosis for Efficacy Evaluation of Therapeutics

AU - Riggs, Michael W

AU - Schaefer, Deborah A.

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Cryptosporidiosis, caused by the apicomplexan parasite Cryptosporidium parvum, is a moderate-to-severe diarrheal disease now recognized as one of the leading causes of morbidity and mortality in livestock globally, and in humans living in resource-limited parts of the world, particularly those with AIDS or malnourished individuals. This recognition has fueled efforts for the discovery of effective therapeutics. While recent progress in drug discovery has been encouraging, there are presently no acceptably effective parasite-specific drugs for the disease. The urgent need for new drug discovery or drug repurposing has also increased the need for refined animal models of clinical disease for therapeutic efficacy evaluation. Here, we describe an acute model of cryptosporidiosis using newborn calves to evaluate well-defined clinical and parasitological parameter outcomes, including the effect on diarrhea severity and duration, oocyst numbers produced, and multiple measures of clinical health. The model is highly reproducible and provides unequivocal direct measures of treatment efficacy on diarrhea severity and parasite replication.

AB - Cryptosporidiosis, caused by the apicomplexan parasite Cryptosporidium parvum, is a moderate-to-severe diarrheal disease now recognized as one of the leading causes of morbidity and mortality in livestock globally, and in humans living in resource-limited parts of the world, particularly those with AIDS or malnourished individuals. This recognition has fueled efforts for the discovery of effective therapeutics. While recent progress in drug discovery has been encouraging, there are presently no acceptably effective parasite-specific drugs for the disease. The urgent need for new drug discovery or drug repurposing has also increased the need for refined animal models of clinical disease for therapeutic efficacy evaluation. Here, we describe an acute model of cryptosporidiosis using newborn calves to evaluate well-defined clinical and parasitological parameter outcomes, including the effect on diarrhea severity and duration, oocyst numbers produced, and multiple measures of clinical health. The model is highly reproducible and provides unequivocal direct measures of treatment efficacy on diarrhea severity and parasite replication.

KW - Bovine model

KW - Clinical evaluation

KW - Cryptosporidiosis

KW - Cryptosporidium

KW - Diarrhea quantitation

KW - Oocyst quantitation

KW - Therapeutic evaluation

UR - http://www.scopus.com/inward/record.url?scp=85071624677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071624677&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-9748-0_15

DO - 10.1007/978-1-4939-9748-0_15

M3 - Chapter

C2 - 31452167

AN - SCOPUS:85071624677

T3 - Methods in Molecular Biology

SP - 253

EP - 282

BT - Methods in Molecular Biology

PB - Humana Press Inc.

ER -